Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
Department of Neurology, University of Michigan, Ann Arbor, MI, USA; Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI, USA; Neurology Service and GRECC, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Parkinsonism Relat Disord. 2014 Jan;20(1):13-6. doi: 10.1016/j.parkreldis.2013.08.021. Epub 2013 Sep 8.
It is unknown whether driving difficulty in Parkinson disease (PD) is attributable to nigrostriatal dopaminergic or extranigral non-dopaminergic neurodegeneration.
To investigate in vivo imaging differences in dopaminergic and cholinergic innervation between PD patients with and without a history of risky driving.
Thirty non-demented PD subjects (10 women/20 men) completed a driving survey. These subjects had previously undergone (+)-[(11)C] dihydrotetrabenazine vesicular monoamine transporter 2 and [(11)C] methyl-4-piperidinyl propionate acetylcholinesterase PET imaging. Acetylcholinesterase PET imaging assesses cholinergic terminal integrity with cortical uptake largely reflecting basal forebrain and thalamic uptake principally reflecting pedunculopontine nucleus integrity.
Eight of thirty subjects reported a history of risky driving (been pulled over, had a traffic citation, or been in an accident since PD onset) while 22 had no such history (safe drivers). There was no difference in striatal dihydrotetrabenazine vesicular monoamine transporter uptake between risky and safe drivers. There was significantly less thalamic acetylcholinesterase activity in the risky drivers compared to safe drivers (0.0513 ± 0.006 vs. 0.0570 ± 0.006, p = 0.022) but no difference in neocortical acetylcholinesterase activity. Using multivariable logistic regression, decreased thalamic acetylcholinesterase activity remained an independent predictor of risky driving in PD even after controlling for age and disease duration.
Risky driving is related to pedunculopontine nucleus-thalamic but not neocortical cholinergic denervation or nigrostriatal dopaminergic denervation in PD. This suggests that degeneration of the pedunculopontine nucleus, a brainstem center responsible for postural and gait control, plays a role in the ability of PD patients to drive.
帕金森病(PD)患者的驾驶困难是由黑质纹状体多巴胺能还是额外的非多巴胺能神经退行性变引起的尚不清楚。
研究有和无高危驾驶史的 PD 患者之间多巴胺能和胆碱能神经支配的体内成像差异。
30 名非痴呆 PD 受试者(10 名女性/20 名男性)完成了驾驶调查。这些受试者之前接受过[+]-[(11)C]二氢四苯并嗪囊泡单胺转运体 2 和[(11)C]甲基-4-哌啶基丙酸乙酰胆碱酯酶 PET 成像。乙酰胆碱酯酶 PET 成像评估胆碱能末梢完整性,皮质摄取主要反映基底前脑和丘脑摄取主要反映脑桥被盖核完整性。
30 名受试者中有 8 名(高危驾驶组)报告有高危驾驶史(PD 发病后被拦下、收到交通罚单或发生事故),而 22 名(安全驾驶组)无此类病史。高危和安全驾驶组之间纹状体二氢四苯并嗪囊泡单胺转运体摄取无差异。高危驾驶组的丘脑乙酰胆碱酯酶活性明显低于安全驾驶组(0.0513±0.006 与 0.0570±0.006,p=0.022),但新皮质乙酰胆碱酯酶活性无差异。使用多变量逻辑回归,即使在控制年龄和疾病持续时间后,丘脑乙酰胆碱酯酶活性降低仍然是 PD 高危驾驶的独立预测因素。
高危驾驶与 PD 中的脑桥被盖核-丘脑但不是新皮质胆碱能神经退行性变或黑质纹状体多巴胺能神经退行性变有关。这表明,负责姿势和步态控制的脑干中心脑桥被盖核的退化在 PD 患者的驾驶能力中起作用。